Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | Chief Financial Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,334 |
Reported balance
After 2024-01-02 transaction · row 1
1 source rowRow 1 · 2024-01-02 · Tax withholding · Disposed 382 · Balance 86,334 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IXYS, LLC
Report date January 17, 2018 · Filed January 18, 2018
Section 16 reporting ended · disclosed 2018-01-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 1
1 source rowRow 1 · 2018-01-17 · Disposition to issuer · Disposed 5,172 · Balance 0 F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.83 · Expires 2024-08-28 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2025-08-28 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.58 · Expires 2026-08-26 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock.
F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option.
F3: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2022 Filed May 24, 2022 16:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $36.99 | $37,988.73 |
DisclosureSEC source: 0001214659-22-007387 · marketforms-56320.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,386 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 22, 2022 Filed Apr 26, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 275 | $34.21 | $9,407.75 |
DisclosureSEC source: 0001214659-22-005841 · marketforms-56026.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,413 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · derivative · entry 8 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,864 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · derivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,148 Underlying: Common Stock · 1,600 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,503 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · derivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,827 Underlying: Common Stock · 3,503 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on April 23, 2019, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,127 | $43.52 | $49,052.11 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,688 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $43.24 to $44.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,493 | $42.71 | $234,630.75 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,815 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $42.23 to $43.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,600 | $23.33 | $37,328.00 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 3,503 | $11.59 | $40,599.77 |
DisclosureSEC source: 0001214659-22-005391 · marketforms-55995.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 457 | $52.91 | $24,179.87 |
DisclosureSEC source: 0001214659-22-004866 · marketforms-55953.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,688 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · derivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 2,000 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · derivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,381 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 180 | $53.68 | $9,662.40 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,145 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F4 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c) Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,230 | $52.81 | $64,951.38 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,325 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $52.47 to $53.35 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,107 | $51.96 | $109,489.41 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,555 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $51.46 to $52.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 2,000 | $23.33 | $46,660.00 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-22-003676 · marketforms-55689.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · derivative · entry 8 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,748 Underlying: Common Stock · 2,000 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · derivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,898 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 640 | $53.66 | $34,345.02 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · nonDerivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $53.50 to $54.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,341 | $52.88 | $70,913.96 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,640 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $52.45 to $53.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,461 | $52.03 | $128,056.90 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,981 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $51.44 to $52.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 2,000 | $23.33 | $46,660.00 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,025 | $53.21 | $54,540.25 |
DisclosureSEC source: 0001214659-22-003108 · marketforms-55522.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,925 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 302 | $55.87 | $16,872.74 |
DisclosureSEC source: 0001214659-22-001139 · marketforms-55141.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,950 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 220 | $77.39 | $17,025.80 |
DisclosureSEC source: 0001214659-22-000943 · marketforms-55098.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,252 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 283 | $77.39 | $21,901.37 |
DisclosureSEC source: 0001214659-22-000330 · marketforms-54931.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,472 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 6,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-013761 · marketforms-54803.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,755 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of October 1, 2021, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · derivative · entry 9 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,330 Underlying: Common Stock · 7,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 491 | $91.35 | $44,852.51 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 8 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,698 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $91.20 to $91.46 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,212 | $90.51 | $200,218.52 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,189 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $90.19 to $90.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,399 | $89.73 | $215,260.59 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,401 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $89.13 to $90.12 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 831 | $88.37 | $73,438.21 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $87.90 to $88.80 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 600 | $87.08 | $52,246.98 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,631 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $86.84 to $87.67 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 267 | $85.72 | $22,887.75 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,231 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $85.28 to $86.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $83.34 | $16,668.00 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,498 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $83.28 to $83.40 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 7,000 | $11.59 | $81,130.00 |
DisclosureSEC source: 0001214659-21-012989 · marketforms-54595.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $110.62 | $113,606.74 |
DisclosureSEC source: 0001214659-21-012189 · marketforms-54360.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,698 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 22, 2021 Filed Oct 26, 2021 19:14 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 275 | $117.41 | $32,287.75 |
DisclosureSEC source: 0001214659-21-010777 · ownership.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,725 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-21-010501 · marketforms-54002.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,330 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,000 | $101.76 | $814,080.00 |
DisclosureSEC source: 0001214659-21-010501 · marketforms-54002.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 16:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 8,000 | $11.59 | $92,720.00 |
DisclosureSEC source: 0001214659-21-010501 · marketforms-54002.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 16:39 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 257 | $105.50 | $27,113.50 |
DisclosureSEC source: 0001214659-21-010289 · marketforms-53984.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 16:33 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $100.49 | $103,203.23 |
DisclosureSEC source: 0001214659-21-008951 · marketforms-53635.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,257 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-21-008685 · marketforms-53594.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,330 Underlying: Common Stock · 6,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,000 | $103.70 | $622,200.00 |
DisclosureSEC source: 0001214659-21-008685 · marketforms-53594.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,000 | $11.59 | $69,540.00 |
DisclosureSEC source: 0001214659-21-008685 · marketforms-53594.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 16:34 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 275 | $117.34 | $32,268.50 |
DisclosureSEC source: 0001214659-21-007856 · marketforms-53386.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,200 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.